礼来公司上市前库存为即将推出的减肥药带来希望

2025-02-21 02:53

Eli Lilly (NYSE:LLY) has raised expectations for its experimental weight loss pill, orforglipron, capitalizing $548.1M in pre-launch inventory in 2024 for the next-gen drug ahead of a potential regulatory nod next year.
The line item indicated in the Indiana-based drugmaker’s 10-K filing on Wednesday reflects LLY's high hopes for the once-daily GLP-1 receptor agonist, a partnership between the company and Japanese pharma Chugai Pharmaceutical (OTCPK:CHGCF) (OTCPK:CHGCY).
“When we believe that future commercialization is probable and the future economic benefit is expected to be realized, we capitalize pre-launch inventory prior to regulatory approval,” LLY said.
Several late-stage trials for orforglipron are currently underway. Its ATTAIN-1 and ATTAIN-2 trials are scheduled to read out in Q3 2025, forming the basis for the company’s regulatory filings anticipated in late 2025 ahead of a potential regulatory nod in 2026 for obesity.

More on Eli Lilly